β2-microglobulin and colorectal cancer among inpatients: a case–control study

• Published in: Scientific reports 2023-07, Vol.13 (1), p.12222-12222, Article 12222
• Main Authors: Wang, Huijie, Zheng, Huanwei, Cao, Xu, Meng, Ping, Liu, Jinli, Zheng, Caihua, Zuo, Haiying, Wang, Zhichao, Zhang, Teng
• Format: Article
• Language: English
• Subjects: 631/67; 631/67/1504; 692/499; Colonoscopy; Colorectal cancer; Colorectal carcinoma; Electronic medical records; Humanities and Social Sciences; Malignancy; multidisciplinary; Regression analysis; Science; Science (multidisciplinary); Sensitivity analysis; β2 Microglobulin
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-39162-x

Β2-microglobulin (β2-M) is associated with various malignancies. However, the relationship between β2-M and colorectal cancer (CRC) remains unclear. We explored the association between β2-M and CRC among inpatients who underwent colonoscopy and explored factors that may modify the association. All consecutive inpatients who underwent colonoscopy were enrolled in a tertiary hospital between April 2015 and June 2022. Inpatients with initial CRC or normal colonoscopies were considered eligible as cases or controls, respectively. Baseline characteristics and laboratory indicators of the participants were collected from electronic medical records. Logistic regression analysis, smooth curve fitting, sensitivity analysis, and subgroup analysis were conducted in the present study. After adjusting for baseline clinical characteristics and laboratory parameters, β2-M was positively associated with CRC (odds ratio [OR] 1.32; 95% confidence interval [CI] 1.11–1.58) among inpatients. When the β2-M level was assigned as tertiles, participants in the highest tertile presented with a higher risk of CRC (OR 2.33; 95% CI 1.57–3.48). A positive linear association was observed between β2-M and CRC with smooth curve fitting. In particular, it may be of great importance to monitor β2-M levels for predicting CRC patients.